Business Description
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Business History
Price Overview
Last updated: Jun 30, 2026 9:29pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -22.61
Total Equity: -$1.26M
Shares: 1,756,844,000
Total Debt: $0.00
Cash: $6.12M
EBITDA: -$39.72M
Total Debt: $0.00
Cash: $6.12M
Revenue: $0.00
Shares: 1,756,844,000
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: -$1.26M
Tax Rate: 0.0%
Equity: -$1.26M
Total Debt: $0.00
Cash: $6.12M
Current Liabilities: $10.41M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$1.26M
Shares: 1,756,844,000
Shares: 1,756,844,000
CapEx: $0.00
Shares: 1,756,844,000
Stock Price: $13.16
Net Income: -$39.72M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 30, 2026 9:29pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $8,138 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $5.9M | $15,070 | $10.4M | $0 | $0 |
| Gross Profit | -$5.8M | $-15,070 | -$10.4M | $0 | $0 |
| Operating Expenses | $4.6M | $31.4M | $8.5M | $16.8M | $40.2M |
| Operating Income | -$8.2M | -$31.4M | -$18.9M | -$16.8M | -$40.2M |
| Net Income | -$12.0M | -$24.3M | -$17.5M | $2.8M | -$39.7M |
| EBITDA | -$9.3M | -$23.9M | -$17.8M | $2.9M | -$39.7M |
| EPS | $-51.77 | $-80.90 | $-35.50 | $2.75 | $-22.61 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 30, 2026 9:29pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $21.4M | $10.7M | $12.6M | $13.3M | $6.1M |
| Total Current Assets | $22.4M | $12.6M | $13.6M | $18.9M | $9.2M |
| Total Assets | $22.4M | $12.6M | $13.6M | $18.9M | $9.2M |
| Current Liabilities | $1.2M | $11.7M | $9.3M | $2.2M | $10.4M |
| Long-Term Debt | $4.9M | $0 | $0 | $0 | $0 |
| Total Liabilities | $15.3M | $15.0M | $9.9M | $2.4M | $10.4M |
| Total Equity | $7.2M | -$2.5M | $3.8M | $16.5M | -$1.3M |
| Retained Earnings | -$78.6M | -$146.0M | -$93.5M | -$90.7M | -$130.4M |
Cash Flow (Annual)
Last updated: Jun 30, 2026 9:29pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$9.4M | -$22.9M | -$10.8M | -$27.2M | -$28.1M |
| Capital Expenditure | $-6,124 | $-2,661 | $0 | $0 | $0 |
| Free Cash Flow | -$9.4M | -$22.9M | -$10.8M | -$27.2M | -$28.1M |
| Acquisitions (net) | $99,702 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $16.2M | -$14.9M | $6.7M | $693,021 | -$7.2M |
Analyst Estimates (Annual)
Last updated: Jun 30, 2026 9:29pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 |
$18.0M $18.0M – $18.0M
|
$73.5M $73.5M – $73.5M
|
$52.4M $52.4M – $52.4M
|
| EBITDA | $0 |
$10.8M $10.8M – $10.8M
|
$44.1M $44.1M – $44.1M
|
$31.5M $31.5M – $31.5M
|
| Net Income |
-$7.1B -$7.1B – -$7.1B
|
-$6.7B -$9.1B – -$4.2B
|
-$8.3B -$8.3B – -$8.3B
|
-$5.4B -$5.4B – -$5.4B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 30, 2026 9:29pm (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -100.0% | — | — | — |
| Gross Profit Growth | +99.7% | -69,208.2% | +100.0% | — |
| Operating Income Growth | -280.8% | +39.8% | +11.0% | -138.7% |
| Net Income Growth | -102.6% | +27.9% | +115.9% | -1,529.3% |
| EBITDA Growth | -156.0% | +25.4% | +116.0% | -1,490.9% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-20 | WYMAN WILLIAM W | A-Award | 11,000.00 | $10.77 | $118,470 |
| 2026-05-20 | WYMAN WILLIAM W | A-Award | 5,500.00 | $10.77 | $59,235 |
| 2026-05-20 | Williams Eugene | A-Award | 11,000.00 | $10.77 | $118,470 |
| 2026-05-20 | Williams Eugene | A-Award | 5,500.00 | $10.77 | $59,235 |
| 2026-05-20 | Warma Neil K | A-Award | 160,000.00 | $10.77 | $1.7M |
| 2026-05-20 | Shafmaster Madge K. | A-Award | 11,000.00 | $10.77 | $118,470 |
| 2026-05-20 | Shafmaster Madge K. | A-Award | 5,500.00 | $10.77 | $59,235 |
| 2026-05-20 | Cashman Neil | A-Award | 50,000.00 | $10.77 | $538,500 |
| 2026-05-20 | Milbury Max A. | A-Award | 18,167.00 | $10.77 | $195,659 |
| 2026-05-20 | Mandel-Brehm Josh | A-Award | 11,000.00 | $10.77 | $118,470 |
| 2026-05-20 | Mandel-Brehm Josh | A-Award | 5,500.00 | $10.77 | $59,235 |
| 2026-05-20 | Kaplan Johanne | A-Award | 50,000.00 | $10.77 | $538,500 |
| 2026-05-20 | Alex Slanix Paul | A-Award | 11,000.00 | $10.77 | $118,470 |
| 2026-05-20 | Alex Slanix Paul | A-Award | 5,500.00 | $10.77 | $59,235 |
| 2026-04-22 | Kirwin Patrick D. | P-Purchase | 4,000.00 | $11.33 | $45,320 |
| 2026-03-05 | Williams Eugene | P-Purchase | 2,000.00 | $24.40 | $48,800 |
| 2026-03-04 | Williams Eugene | P-Purchase | 2,000.00 | $24.00 | $48,000 |
| 2026-03-03 | Williams Eugene | P-Purchase | 1,000.00 | $21.89 | $21,890 |
| 2026-03-02 | Williams Eugene | P-Purchase | 1,000.00 | $22.53 | $22,530 |
| 2026-02-03 | ABG V-SIV IX Ltd | 0.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).